All enrolled sufferers who obtained no less than one dose of zosuquidar or placebo throughout induction were monitored for the prevalence of adverse activities (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse gatherings have been linked to the duration of prolonged and substantial myelosuppression as is https://johnathaneyriy.blogdon.net/the-5-second-trick-for-sulfoxaflor-44198352